Categorized | Stock Profiles

GTHP (Guided Theraputics Inc.)


Share Button

gthp logoGuided Theraputics Inc. (GTHP) is a U.S. based medical technology company who focuses on the development and marketing of medical devices, specifically a rapid and painless testing platform for the early detection of cervical disease known as the LuViva Advanced Cervical Scan.

After breast cancer, cervical cancer is the second most common disease in woman with over 500,000 new women diagnosed worldwide in 2012. However, research indicates approximately 80% or more women who receive an abnormal result in their pre-screening for cervical disease eventually are diagnosed with having a false positive result – only after undergoing the worrisome and painful biopsy and colposcopy. Aiming to reduce the number of misdiagnoses and prevent cervical cancer, GTHP has developed a revolutionary platform using a patented technology that uses a non-invasive light method, known as biophotonics, that sees, scans, and detects any structural and/or chemical changes below the surface of the tissue. Contrary to conventional testing methods such as pathology or cytology, GTHP’sLuViva Advanced Cervical Scan can indicate the early stages of cancer up to two years earlier and eliminate nearly 40% of the often too common false positive Pap and HPV results as the technology is designed to provide immediate results after the examination and does not require the traditional, painful biopsy tissue sample that may take days or weeks for a result.

Currently, the company’s technology is distributed among 47 countries including Kenya, Costa Rica, Bulgaria, Indonesia, Bangladesh,  and other undeveloped regions where the means to screen women for cervical cancer are not meant due to infrastructure restrictions. Additional successful distribution is seen with GTHP’s recent 4-year, $14 million Contract with the Turkish Ministry of Healthand is currently Under Review by the U.S. Federal Drug Administration. However, with the need of future testing and development, GTHP’s preliminary studies have concluded that the company’s patented technology can also apply to other forms of carcinoma such as esophageal, head and neck, anal, colorectal, and skin cancers.

 

Website(s): www.guidedinc.com

 

Market Outlook

  • The global market for cervical cancer screening and diagnostics is currently estimated at $6 billion and is projected to top $9 billion by 2020.
  • Several regions around the world lack access to effective screening and services that facilitate early detection and treatment.
  • In developing countries, cervical cancer remains as the leading cause of cancer death for women of childbearing age due to the restrictions of laboratory infrastructure.
  • Between the countries of Kenya, Bangladesh, and Indonesia, there is a population of approximately 150 million women who will benefit from cervical cancer screening.
  • In 2012, there were 528,000 cases of invasive cancer worldwide with 266,000 cases resulting in death.
  • In the U.S. there are approximately 500,000 cases of pre-cancer.
  • The American Cancer Society estimates 12,900 new cases of invasive cervical cancer will be diagnosed by the end of 2015 in the U.S.
  • Approximately 55-60 million Pap tests are conducted annually in the U.S. with an estimated 5.5 – 6 million follow-up referrals.

This post was written by:

- who has written 2169 posts on StockRockandRoll.


Contact the author

Comments are closed.


© 2020 MJ Capital, LLC | All rights reserved